Legacy Investor
1.5K posts
@arabwealthy
I bet my networth on high quality stocks. A realistic bull, and a history lover. Early $Hims $OSCR and $ZETA investor.
@MMatters22596 I think we can see $AMD crossing $250 before end of 2026. It has not been following the tech uptrend . $JD is also going up in my opinion.
“The time to buy is when there’s BLOOD IN THE STREETS.” If you ask me, in $HIMS' case, sentiment is already extremely negative — hardly anyone seems to believe in the company anymore. That’s usually when things start to get interesting. My defined trend reversal zone lies between $17.76 and $10.73 (yellow box). From the current structure, I expect a counter-trend move followed by one final downward leg — although it’s entirely possible that $HIMS has already bottomed out. A sustained break above the green line at $32.05 would confirm that the bottoming process is complete. What’s your current view on $HIMS?
@Fibonacci_TA @Freedom_By_40 Good charts. Bad Fibby! 😆
BREAKING: Unemployed Americans with four-year college degrees have hit a record, per Bloomberg.
A few notes about the BofA update, as it came out early this morning, before the details of the $HIMS x $NVO deal were public: 1. BofA views the partnership as a clear positive for $HIMS, particularly the withdrawal of the lawsuit, which removes a major overhang for the stock. 2. BofA thinks the partnership reflects favorably on Hims' ability to partner with pharma companies and could lead to subsequent partnerships. 3. One of BofA's main assumptions was that Hims would be required to stop selling compounded GLP-1 drugs. This of course did NOT happen. Hims has said they will stop advertising compounded GLP-1s and will push the branded options; however, Hims also said it will continue to offer compounded GLP-1s for customers who need them.
🚨 BREAKING: THE LEGAL BATTLE BETWEEN $HIMS AND NOVO NORDISK IS OVER $NVO OFFICIALLY DROPS LAWSUIT AGAINST $HIMS
